AnBogen Therapeutics, Inc. is a precision oncology company that develops therapies for cancer treatment. AnBogen leverages diverse roots, scientific knowledge, and expertise in drug discovery and development to create therapies aimed at transforming cancer treatment.

AnBogen Therapeutics, Inc.

Anbogen Therapeutics is a clinical stage precision oncology company dedicated in developing first/best-in-class personalized therapeutics and making difference in patients' life. We bridge the gap between discovery candidates and proof-of-concept indications to challenge the unmet needs.

Headquartered in Taiwan, we are advancing a pipeline of precision medicines for the treatment of solid tumors. Currently with three assets including ABT-101 and ABT-301 under clinical development. 


AnBogen Therapeutics

Anbogen Therapeutics is pleased to announce the successful closing of a USD 7.3M oversubscribed A+ round financing, bringing our total Series A funding to USD 19.8M. This funding will advance the Phase II clinical trial of ABT-301 in combination with PD-1 inhibitors for treating microsatellite stable (MSS) metastatic colorectal cancer.

Read the complete news release here: https://reurl.cc/MOEGQ3
#SeriesA+ #AnbogenTherapeutics #ABT301 #immunecheckpointinhibitors

Delighted to announce the successful completion of Anbogen Therapeutics' Series A, with USD 12.5 million raised. Gratitude to our investors for their support as we advance in developing precision anti-cancer drugs. Read the complete news release here: https://lnkd.in/gpacKFWF
#SeriesA #Biotech #Innovation #AnbogenTherapeutics

Happy New Year from all of us at Anbogen! As we enter 2024, we're not only celebrating the possibilities ahead but also eagerly anticipating sharing more of our precision drug development progress with you this year. Wishing everyone a year filled with success, health, and exciting discoveries!
#ABT-101 #ABT-301 #ABT-202

news_impact_assignment_basic

key_people

network_dossier

public_peers

news_daily_refresh

news_processing_daily_refresh

news_impact_assignment_daily

news_processing_basic

legal

legal_dossier

bundesanzeiger

events_dossier

partnerships_market_presence_dossier

partnerships_market_presence

company_dossier

network

strategic_challenges

industry_trends

strategic_challenges_dossier

industry_trends_dossier

company_summary

events

network_mapping

transactions_dossier

swot_dossier

merger_acquisitions

signals

financial_statements

crunchbase_trigger

crunchbase_profile

li_profile

financials_download_nd

private_financials

swot_analysis

financial_legal_advisories

company_structure

industry_analysis

financial_analysis

funding_rounds_analysis

regulatory_analysis

competition_analysis

news_impact_assignment_advanced

news_processing_advanced

news_advanced

purchaser_profile

network_onboarding

translate_crunchbase_fundingrounds

peers

customer_profile

news_basic

valuation

news impact assignment basic	general
public peers	general	Aug 5, 2024 3:13 PM	d3b5f553
news daily refresh	general
news processing daily refresh	general
news impact assignment daily	general
news processing basic	general
company summary	general
signals	general
crunchbase trigger	general
crunchbase profile	general
li profile	general	Aug 5, 2024 3:13 PM	d50d5681
translate crunchbase fundingrounds	general
peers	general	Aug 5, 2024 3:13 PM	0bed5dcc
news basic	general	Aug 5, 2024 3:13 PM	e9770fe9
bundesanzeiger	filings
merger acquisitions	company_analysis
financials download nd	financials
private financials	financials

COM:ANBOGEN

AnBogen Therapeutics, Inc.